metoprolol has been researched along with ANS (Autonomic Nervous System) Diseases in 5 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (40.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Man in't Veld, AJ | 1 |
Boomsma, F | 1 |
Schalekamp, MA | 1 |
Pasquina, PF | 1 |
Houston, RM | 1 |
Belandres, PV | 1 |
de Milliano, PA | 1 |
van Eck-Smit, BL | 1 |
de Groot, AC | 1 |
Lie, KI | 1 |
Forslund, L | 1 |
Björkander, I | 1 |
Ericson, M | 1 |
Held, C | 1 |
Kahan, T | 1 |
Rehnqvist, N | 1 |
Hjemdahl, P | 1 |
Rochette, G | 1 |
Lecomte, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-09-23 | Recruiting | ||
The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease[NCT03775096] | Phase 2 | 15 participants (Anticipated) | Interventional | 2019-04-04 | Recruiting | ||
Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
Intervention | Abscence seizures (Number) |
---|---|
Week 8 Baseline | 165 |
Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
Intervention | General tonic-clonic seizures (Number) |
---|---|
Week 8 Baseline | 39 |
Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
Intervention | Myoclonic seizures (Number) |
---|---|
Week 8 Baseline | 116 |
Week 12 Verapamil 4mg/kg/Day | 175 |
1 trial available for metoprolol and ANS (Autonomic Nervous System) Diseases
Article | Year |
---|---|
Prognostic implications of autonomic function assessed by analyses of catecholamines and heart rate variability in stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Biomarkers; | 2002 |
4 other studies available for metoprolol and ANS (Autonomic Nervous System) Diseases
Article | Year |
---|---|
Effects of beta-adrenoceptor agonists and antagonists in patients with peripheral autonomic neuropathy.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Albuterol; Amyloidosis; Autonomi | 1982 |
Beta blockade in the treatment of autonomic dysreflexia: a case report and review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Autonomic Nervous System Diseases; Cervica | 1998 |
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp | 2000 |
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp | 2000 |
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp | 2000 |
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp | 2000 |
[Several cardiovascular manifestations induced by vibrational stimuli].
Topics: Adult; Autonomic Nervous System Diseases; Cardiovascular Diseases; Fingers; Humans; Hypertension; Me | 1985 |